Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Protein (His), Active

Name: Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Protein (His), Active
Brand: Beta LifeScience
SKU: BLC-05599P
Availability: InStock

Greater than 95% as determined by SDS-PAGE.

Collections: Coronaviruses, Featured viral antigens molecules, High-quality recombinant proteins, Viral antigen recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Protein (His), Active is produced by our Mammalian cell expression system. This is a protein fragment.
Purity	Greater than 95% as determined by SDS-PAGE.
Endotoxin	Less than 1.0 EU/μg as determined by LAL method.
Activity	Immobilized Human ACE-2-His at 10μg/ml (100μl/well) can bind 2019-nCoV S Protein RBD-mFc. The ED50 of 2019-nCoV S Protein RBD-mFc is 19.97 ng/ml.
Uniprotkb	Q9BYF1
Target Symbol	ACE2
Synonyms	ACE 2; ACE related carboxypeptidase; ACE-related carboxypeptidase; ACE2; ACE2_HUMAN; ACEH; Angiotensin converting enzyme 2; Angiotensin converting enzyme homolog; Angiotensin converting enzyme like protein; Angiotensin I Converting Enzyme (peptidyl dipeptidase A) 2; Angiotensin I converting enzyme 2; Angiotensin-converting enzyme homolog; DKFZP434A014; EC 3.4.17; metalloprotease MPROT 15; Metalloprotease MPROT15; OTTHUMP00000022963; Processed angiotensin-converting enzyme 2
Species	Homo sapiens (Human)
Expression System	Mammalian cell
Tag	C-6His
Complete Sequence	QSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVPFGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMSLSAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEPVPHDETYCDPASLFHVSNDYSFIRYYTRTLYQFQFQEALCQAAKHEGPLHKCDISNSTEAGQKLFNMLRLGKSEPWTLALENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPYADQSIKVRISLKSALGDKAYEWNDNEMYLFRSSVAYAMRQYFLKVKNQMILFGEEDVRVANLKPRISFNFFVTAPKNVSDIIPRTEVEKAIRMSRSRINDAFRLNDNSLEFLGIQPTLGPPNQPPVS
Expression Range	18-740aa
Protein Length	Partial
Mol. Weight	84.63 kDa
Research Area	Cardiovascular
Form	Liquid or Lyophilized powder
Buffer	0.2 μm Filtered 20 mM Tris-HCl, 300 mM NaCl, 1 mM ZnCl2, 10% Glycerol, pH 7.4
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.

Target Details

Target Function	Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis. Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and anti-proliferation agent, counterbalancing the actions of the vasoconstrictor angiotensin II. Also removes the C-terminal residue from three other vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin, but is not active on bradykinin. Also cleaves other biological peptides, such as apelins (apelin-13, Non-functional as a carboxypeptidase.; (Microbial infection) Acts as a receptor for human coronaviruses SARS-CoV and SARS-CoV-2, as well as human coronavirus NL63/HCoV-NL63.; (Microbial infection) Non-functional as a receptor for human coronavirus SARS-CoV-2.
Subcellular Location	[Processed angiotensin-converting enzyme 2]: Secreted.; Cell membrane; Single-pass type I membrane protein. Cytoplasm. Cell projection, cilium. Apical cell membrane.; [Isoform 2]: Apical cell membrane.
Protein Families	Peptidase M2 family
Database References	HGNC: 13557 OMIM: 300335 KEGG: hsa:59272 STRING: 9606.ENSP00000252519 UniGene: PMID: 30056001 In a Chinese Han population, five single-nucleotide polymorphisms (SNP) (rs1514283, rs4646155, rs4646176, rs2285666, and rs879922) in ACE2 gene were determined to significantly associate with essential hypertension in female participants, while no SNP locus was linked to male group. PMID: 30335025 ACE2 and other enzymes can form ANG-(1-7) directly or indirectly from either the decapeptide ANG I or from ANG II. [review] PMID: 29351514 Suggest a potential role for ACE2 polymorphism in postexercise hypotension in hypertensive medicated individuals. PMID: 27925380 ACE2 SNPs and haplotypes are associated with circulating angiotensin-(1-7) levels. PMID: 28895159 we found an interaction between ACE2 and AGTR1 in structuralatrial fibrillation patients in a Chinese Han population PMID: 29441892 results suggest that ACE2, TNNI3K and CALM3 polymorphisms are associated with increased risk of hypertrophic cardiomyopathies and dilated cardiomyopathies and may act as disease modifiers of these diseases. PMID: 28744816 Elevated plasma ACE2 is significantly associated with more advanced LA structural remodeling in atrial fibrillation. PMID: 27738071 Overexpression of ACE2 in monocytes led to reduced endothelial adhesion, transmigration and downregulation of adhesion-related molecules and results in atherosclerosis. PMID: 28186543 These results indicated that aberrant methylation of the ACE2 promoter may be associated with EH risk. In addition, sex may significantly influence ACE2 methylation. PMID: 28440441 ACE2 rs2106809 is an important predictive factor of the response to antihypertensive treatment with ACE inhibitors in Chinese female hypertensive patients. PMID: 27121444 In islets from db/db mice, ACE2 over-expression increased intracellular calcium influx and restored impaired mitochondrial oxidation, potentially causing an increase in GSIS. These results shed light on the potential roles of ACE2 in mitochondrial metabolism, moreover, may improve our understanding of diabetes. PMID: 29128354 ACE2 may have a role in silent atherosclerosis in patients with chronic kidney disease; it counterbalances the vasoconstrictor adverse effects of angiotensin II by its conversion PMID: 27615597 This study reveals an elevated serum concentration of ACE2 and independent associations between serum ACE2 and echocardiographic parameters in hypertensive patients. PMID: 28223093 The findings of this study indicate that ACE-2 activity is reduced in AD and is an important regulator of the central classical ACE-1/Ang II/AT1R axis of renin-angiotensin system, and also that dysregulation of this pathway likely plays a significant role in the pathogenesis of Alzheimer's disease. PMID: 27884212 Overexpression of ACE2 ameliorates Abeta-induced inflammatory response by activating the ACE2/Ang-(1-7)/Mas axis in human RPE cells. PMID: 28605813 Although further studies are required to determine how clusterin suppresses non-specific cellular uptake in phagocytes, our data suggest that clusterin plays a key role in the stealth effect of not only pegylated nanoparticles but also non-pegylated nanoparticles. PMID: 27983983 The ACE2 G8790A polymorphism in type 2 diabetes mellitus patients was correlated with cerebral stroke, and the A allele might be a risk factor of type 2 diabetes mellitus combined with cerebral stroke. PMID: 27500554 ollectrin, an ACE2 homolog with no catalytic activity, regulates blood pressure through an NO-dependent mechanism. Large body of experimental data confirmed sustained beneficial effects of ACE2/Ang-(1-7)/Mas receptor axis activation on hypertension and vascular injury. PMID: 27889958 The potential contribution of the ACE2 to cardiovascular disease progression was addressed. PMID: 27965422 Serum ACE2 activity was significantly lower in acute ischemic stroke as compared to both control and stroke-alert patients, followed by an increase to control levels at three days. PMID: 27488276 Here, we review the role and effects of ACE2, ACE2 activators, Ang-(1-7) and synthetic Mas receptor agonists in the control of inflammation and fibrosis in cardiovascular and renal diseases and as counter-regulators of the ACE-Ang II-AT1 axis. PMID: 26995300 ACE2 overexpression inhibited cell growth. PMID: 27460845 Downregulation of ACE2/Ang-(1-7)/Mas axis stimulates breast cancer metastasis through the activation of store-operated calcium entry and PAK1/NF-kappaB/Snail1 pathways. PMID: 27063099 The circulating ACE2 and Ang-(1-7) levels were related to neither rs4646155 nor rs879922 in female or male patients.In conclusion, the rs2106809 polymorphism of the ACE2 gene may be a determinant of the circulating Ang-(1-7) level in female patients with hypertension, suggesting a genetic association between circulating Ang-(1-7) levels and ACE2 gene polymorphisms in patients with hypertension. PMID: 27310975 These results indicated that angiotensin-(1-7)/ACE2/Mas axis may reduce liver lipid accumulation partly by regulating lipid-metabolizing genes through ATP/P2 receptor/CaM signaling pathway. PMID: 26883384 ACE-2 significantly increased when IMR-90 were hypoxic prior to hyperoxic exposure with no recovery. PMID: 27093376 Imbalanced down-regulation of ACE and ACE2 mRNA expression levels may play an important role in the development and progression of thoracic aortic aneurysmal dilatation and subsequently dissection. PMID: 25237166 These results suggest that the ACE2 G8790A and rs2106809 polymorphisms may be associated with essential hypertension risk. PMID: 25237167 ACE and ACE2 expression at the mRNA and protein levels are significantly increased in the myocardium of patients with heart failure. PMID: 25869724 Multivariable regression analysis revealed that urinary L-FABP and urinary albumin/ creatinine ratio were significantly associated with urinary ACE2 levels. PMID: 26067610 ACE2 and Ang-(1-7) significantly inhibit early atherosclerotic lesion formation via protection of endothelial function and inhibition of inflammatory response. PMID: 25721616 ACE-2 is expressed in fetal human lung fibroblasts but is significantly decreased by hyperoxic gas PMID: 25665060 urinary ACE2 increased in type 2 diabetic patients with various degrees of albuminuria PMID: 25791940 soluble ACE2 is involved in the pathomechanism of hypertension and heart failure. PMID: 24691269 Decrease in circulating ACE2 activity was associated with cardiovascular disease in patients with chronic kidney disease. PMID: 25813276 By genetic replenishment of ACE2 and pharmaceutical use of ARB, restored ACE2 level mitigated GBC growth. Our results supported the rationale for the use of ARB in GBC patients for potential therapeutic benefit PMID: 25663464 There is no clear association between ACE2 gene A9570G polymorphisms and childhood primary nephrotic syndrome. PMID: 25815490 Our results revealed that SNPs rs2074192 and rs714205 in ACE2 gene were associated with the susceptibility of DR and PDR. PMID: 25359286 Olmesartan may uniquely increase urinary ACE2 level in hypertensive patients, which could potentially offer additional renoprotective effects. PMID: 24842388 Hepatocellular carcinoma patients with higher level of ACE2 expression had longer survival time than those with lower level of ACE2 expression. PMID: 25701390 Urinary ACE2 activity and protein expression are increased in type 1 diabetes patients prior to the onset of clinical complications. PMID: 24920267 Brain endoplasmic reticulum stress does not contribute to DOCA-salt hypertension and ACE2 blunts neurogenic hypertension independently of ER stress. PMID: 25519733 Partial loss of ACE2 is sufficient to enhance the susceptibility to heart disease. PMID: 24728465 These data demonstrate that MSCs modified to overexpress the ACE2 gene can produce biologically active ACE2 protein over a sustained period of time and have an enhanced ability to promote endothelial repair after LPS challenge PMID: 25200929 ACE2 cleavage is regulated by influenza A H1N1 neuraminidase. PMID: 24662240 among females ACE2 rs2106809 polymorphisms,and among males ACE2 rs2106809 polymorphism and alcohol consumption are associated with essential hypertension PMID: 24112034 Data suggest angiotensin (ANG) converting enzyme 2/ANG-II-(1-7)/proto-oncogene protein Mas axis regulates inflammation/fibrosis, cell proliferation, and leukocyte recruitment/activation; main topic here is kidney/inflammatory renal disease. [REVIEW] PMID: 23488800 ACE2 and FZD1 are prognosis markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of gallbladder. PMID: 23921915 ACE2 overexpression in the rostral ventrolateral medulla attenuates the enhanced tonically active glutamatergic input in SHRs, which may be an important mechanism underlying the beneficial effect of central ACE2 to hypertension. PMID: 24838502

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.